[Federal Register Volume 60, Number 16 (Wednesday, January 25, 1995)] [Notices] [Page 4920] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 95-1805] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Advisory Committee on Immunization Practices; Meeting In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting: Name: Advisory Committee on Immunization Practices. Times and Dates: 8:30 a.m.-6:30 p.m., February 9, 1995. 8:15 a.m.-4:45 p.m., February 10, 1995. Place: CDC, Auditorium A, Building 2, 1600 Clifton Road, NE, Atlanta, Georgia 30333. Status: Open to the public, limited only by the space available. Purpose: The committee is charged with advising the Director, CDC, on the appropriate uses of immunizing agents. Matters to be Discussed: The committee will discuss recommendations for prevention of hepatitis A: Hepatitis A vaccine and immune globulin; revised recommendations for hepatitis B vaccination; update on varicella vaccine; status on principles and guidelines for combination products; vaccines for children (VFC): influenza vaccine in VFC, hepatitis B for adolescents in VFC, hepatitis A, MMR2--expanded use in VFC; pneumococcal polysaccharide vaccine; adolescent vaccination; poliomyelitis prevention; influenza: 1995-96 influenza vaccine strain selection, 1995-96 influenza vaccine and antiviral recommendations, influenza- associated morbidity during pregnancy, assessment of BBS risk associated with 1993-94 and 1994-95 influenza vaccination, optimal needle length for intramuscular injection into the deltoid, national estimates of influenza vaccination rates; update on meningococcal recommendation; report of a meeting regarding conflicting immunization guidelines and harmonization of the Advisory Committee on Immunization Practices/American Academy of Pediatrics recommendations with the Food and Drug Administration labeling; update on simplification; progress towards 1996 disease reduction goals; recommendations for immunization linkage with the women's, infants, and children program; vaccine safety; an update on the Injury Compensation Program; an update on the National Vaccine Program; and a presentation on acellular pertussis. Other matters of relevance among the committee's objectives may be discussed. Agenda items are subject to change as priorities dictate. For Further Information Contact: Gloria A. Kovach, Committee Management Specialist, CDC (1-B72), 1600 Clifton Road, NE., Mailstop A20, Atlanta, Georgia 30333, telephone 404/639-3851. Dated: January 18, 1995. William H. Gimson, Acting Associate Director for Policy Coordination, Centers for Disease Control and Prevention (CDC). [FR Doc. 95-1805 Filed 1-24-95; 8:45 am] BILLING CODE 4163-18-M